Keyphrases
Trabectedin
100%
Advanced Soft Tissue Sarcoma
66%
Sarcoma
66%
Soft Tissue Sarcoma
38%
Pseudotumor
33%
IgG4-related Disease (IgG4-RD)
33%
Mandible
33%
Radiation Therapy
33%
Myxoid Liposarcoma
33%
HMGA1
33%
Radiotherapy
33%
Phase I Study
33%
DNA Repair Genes
33%
Response Predictors
33%
Inflammatory Pseudotumor
16%
Bone Destruction
16%
Cervicofacial
16%
Differential Diagnosis
16%
Diagnostic Criteria
16%
Clinical Manifestations
16%
Differential Treatment
16%
Choi Criteria
13%
Antitumor Activity
13%
Mammalian Target of Rapamycin (mTOR)
8%
Leiomyosarcoma
8%
Predictive Biomarker
7%
DNA Damage Repair
7%
Gene Signature
7%
Recommended Dose
6%
Residual Tumor
6%
Sepsis
6%
Transaminitis
6%
Dose Level
6%
Special Sensitivity
6%
Catheter-related Infections
6%
Safety Profile
6%
Dose-limiting Toxicity
6%
Preclinical Data
6%
Synergistic Effect
6%
One Dose
6%
Operative
6%
Phase II Study
6%
Patient-completed
6%
3-cycle
6%
Response Evaluation Criteria in Solid Tumors (RECIST)
6%
RECIST Criteria
6%
Tumor Size
6%
Progression-free Survival
6%
Transcriptomics
6%
Tumor Growth
5%
Medicine and Dentistry
Trabectedin
100%
Soft Tissue Sarcoma
100%
Connective Tissue Cancer
66%
Immunoglobulin G4 Related Disease
33%
Lower Jaw
33%
Pseudotumor
33%
DNA Repair
33%
DNA A
33%
Myxosarcoma
33%
Radiation Therapy
33%
Diagnosis
16%
Plasma Cell Granuloma
16%
Bone Destruction
16%
Differential Diagnosis
16%
Neoplasm
14%
Biological Marker
11%
Antineoplastic Activity
11%
Tumor Progression
8%
Leiomyosarcoma
8%
Gene Expression Profiling
6%
Transcriptomics
6%
Progression Free Survival
6%
Mammalian Target of Rapamycin Inhibitor
5%
Mammalian Target of Rapamycin
5%
Messenger RNA
5%
Cell Death
5%
Catheter Infection
5%
Elevated Transaminases
5%
Recommended Drug Dose
5%
Sepsis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Trabectedin
100%
Soft Tissue Sarcoma
100%
Connective Tissue Cancer
66%
Myxosarcoma
33%
DNA A
33%
Neoplasm
20%
Antitumor Activity
16%
Biological Marker
11%
Leiomyosarcoma
8%
Tumor Growth
8%
Catheter Infection
8%
Hypertransaminasemia
8%
Sepsis
8%
Progression Free Survival
6%
Mammalian Target of Rapamycin Inhibitor
5%
Messenger RNA
5%
